https://www.selleckchem.com/pr....oducts/SB-202190.htm
Treatment discontinuations and death during treatment were mainly due to disease progression. Twenty-two (41%) patients received further treatment; 11/22 are still alive, including one after CAR-T cells, and two after stem cell transplantation. Our data confirm that Pola-BR is a promising treatment for rrDLBCL patients, inducing an adequate response rate with acceptable toxicity. Pola-BR could be used as bridging therapy before further consolidative treatments. The quality characteristics and stability of phenolic by-products from Col
Respect!
Kommentar
Delen
